A Phase 1 Dose-escalation and Expansion Study of In Vivo BCMA-CAR T Cell Therapy (VV169) in Patients With Relapsed or Refractory Multiple Myeloma
A Phase 1 Dose-escalation and Expansion Study of In Vivo BCMA-CAR T Cell Therapy (VV169) in Patients With Relapsed or Refractory Multiple Myeloma
Recruiting · NCT07802717 · Registry updated 2026-09-21Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Phase 1 Dose-escalation and Expansion Study of In Vivo BCMA-CAR T Cell Therapy (VV169) in Patients With Relapsed or Refractory Multiple Myeloma | Multiple Myeloma Refractory; Multiple Myeloma in Relapse | Recruiting | Phase 1 | 2026-09-21 | NCT07802717 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Mayo Clinic | 970 |
| Vyriad, Inc. | 3 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| The Mayo Clinic | Rochester | United States | 1 |